Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MNMD Stock Summary
Top 10 Correlated ETFs
MNMD
In the News
PLTR, MNMD, ODD: Finding Value in the Market
Hilary Kramer discusses finding value in the market. She talks about her stock picks which include Palantir (PLTR), Mind Medicine (MNMD), Oddity (ODD), Prairie Operating (PROP), Starbucks (SBUX), and Arm Holdings (ARM).
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag
The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.
Psychedelics stocks fly as FDA recognizes Mind Medicine's LSD drug as breakthrough therapy
Psychedelics stocks traded higher on Thursday as investor optimism returned to the sector on the news that MindMed (NASDAQ:MNMD, NEO:MMED)'s LSD drug candidate was granted breakthrough therapy status by the US Food and Drug Administration (FDA) for the treatment of generalized anxiety disorder (GAD). Shares of MindMed (NASDAQ:MNMD, NEO:MMED) led the charge, gaining 54% at US$9.15 in the mid-afternoon.
Why Is MindMed (MNMD) Stock Up 32% Today?
MindMed (NASDAQ: MNMD ) stock is on the rise Thursday after the clinical-stage biopharmaceutical company received breakthrough therapy designation from the Food and Drug Administration (FDA). This designation covers the company's MM120 program in development to treat generalized anxiety disorder.
Mind Medicine's LSD drug candidate awarded FDA breakthrough therapy designation; shares soar
MindMed (NASDAQ:MNMD, NEO:MMED) shares soared more than 26% higher before Thursday's opening bell after the biopharmaceutical firm revealed that its drug candidate MM120 has been awarded breakthrough therapy status from the US Food and Drug Administration (FDA) for the treatment of generalized anxiety disorder (GAD). MM120 is the tartrate sale form of lysergide (LSD) being developed by MindMed (NASDAQ:MNMD, NEO:MMED) for GAD and other potential applications in brain health disorders.
MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024. The program will provide an update on MM120 in Generalized Anxiety Disorder (GAD), including 12-week topline safety, efficacy, and durability results from the Company's Phase 2b tria.
Why Is MindMed (MNMD) Stock Up 8% Today?
A positive news update for Mind Medicine (NASDAQ: MNMD ) is elevating the entire psychedelic treatment sector today. Specifically, the U.S. Food and Drug Administration (FDA) has just granted midomafetamine capsules (MDMA) a priority review.
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year.
What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock
Mind Medicine (MindMed) Inc. (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Mind Medicine's MM-120 shows promise in Phase 2b trial for Generalized Anxiety Disorder
Mind Medicine (MindMed (NASDAQ:MNMD, NEO:MMED)) has announced encouraging results from its Phase 2b clinical trial of MM-120 in treating Generalized Anxiety Disorder (GAD). MM-120, a single-dose lysergide d-tartrate, demonstrated statistically significant and clinically meaningful improvements over placebo at Week 4, meeting its primary endpoint.
MNMD Financial details
MNMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-08-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.94 | -1.92 | -3.4 | -1.53 | -2.44 | |
Operating cash flow per share | -0.55 | -1.33 | -1.67 | -1.62 | -1.64 | |
Free cash flow per share | -1.37 | -1.33 | -1.67 | -1.62 | -1.64 | |
Cash per share | 0.05 | 4.51 | 4.88 | 4.61 | 2.55 | |
Book value per share | 7.22 | 4.27 | 5.54 | 4.89 | 2 | |
Tangible book value per share | 7.22 | 4.27 | 4.56 | 4.13 | 1.47 | |
Share holders equity per share | 7.22 | 4.27 | 5.54 | 4.89 | 2 | |
Interest debt per share | 0 | 0.01 | 0.01 | 0.05 | 0.36 | |
Market cap | 267.48K | 811.97M | 566.71M | 67.89M | 143.32M | |
Enterprise value | 249.55K | 731.88M | 433.17M | -74.18M | 57.74M | |
P/E ratio | -0.24 | -23.81 | -6.09 | -1.44 | -1.5 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -1.29 | -34.41 | -12.37 | -1.35 | -2.23 | |
PFCF ratio | -0.51 | -34.41 | -12.37 | -1.35 | -2.23 | |
P/B Ratio | 0.1 | 10.7 | 3.74 | 0.45 | 1.83 | |
PTB ratio | 0.1 | 10.7 | 3.74 | 0.45 | 1.83 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -0.54 | -22.16 | -4.62 | 1 | -0.64 | |
EV to operating cash flow | -1.2 | -31.02 | -9.45 | 1.48 | -0.9 | |
EV to free cash flow | -0.48 | -31.02 | -9.45 | 1.48 | -0.9 | |
Earnings yield | -4.17 | -0.04 | -0.16 | -0.7 | -0.67 | |
Free cash flow yield | -1.95 | -0.03 | -0.08 | -0.74 | -0.45 | |
Debt to equity | 0 | 0 | 0 | 0 | 0.18 | |
Debt to assets | 0 | 0 | 0 | 0 | 0.11 | |
Net debt to EBITDA | 0.04 | 2.42 | 1.42 | 1.91 | 0.94 | |
Current ratio | 14.76 | 27.1 | 13.18 | 8.16 | 3.22 | |
Interest coverage | 0 | -201.4 | -268.42 | -44.37 | 0 | |
Income quality | 0.19 | 0.7 | 0.49 | 0.88 | 0.67 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0.16 | 0.14 | 0.16 | |
Capex to operating cash flow | 1.51 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -46.9 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 21.85 | 13.59 | 20.58 | 12.98 | 10.48 | |
ROIC | -0.17 | -0.44 | -0.63 | -0.37 | -1.02 | |
Return on tangible assets | -0.38 | -0.42 | -0.68 | -0.32 | -0.92 | |
Graham Net | -0.47 | 4.19 | 4.43 | 3.99 | 1.36 | |
Working capital | 2.74M | 78.51M | 126.81M | 128.16M | 71.63M | |
Tangible asset value | 2.74M | 75.87M | 124.88M | 127.31M | 57.69M | |
Net current asset value | 2.74M | 75.87M | 124.88M | 126.98M | 57.47M | |
Invested capital | 0 | 0 | 0 | 0 | 0.18 | |
Average receivables | 0 | 2.54K | 0 | 0 | 0 | |
Average payables | 0 | 1.01M | 3.1M | 3.14M | 3.12M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 582.94 | 239.07 | 477.43 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0.63 | 1.53 | 0.76 | |
Inventory turnover | -792.97K | 0 | 0 | 0 | 0 | |
ROE | -0.41 | -0.45 | -0.61 | -0.31 | -1.23 | |
Capex per share | -0.83 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0.13 | -0.72 | -0.76 | -0.45 | -0.59 | |
Operating cash flow per share | -0.42 | -0.35 | -0.36 | -0.42 | -0.49 | |
Free cash flow per share | -0.42 | -0.35 | -0.36 | -0.42 | -0.49 | |
Cash per share | 4.61 | 3.4 | 3.03 | 2.96 | 2.48 | |
Book value per share | 4.89 | 3.42 | 2.75 | 2.42 | 1.94 | |
Tangible book value per share | 4.13 | 2.82 | 2.18 | 1.88 | 1.43 | |
Share holders equity per share | 4.89 | 3.42 | 2.75 | 2.42 | 1.94 | |
Interest debt per share | 0.04 | 0.04 | 0 | 0.35 | 0.35 | |
Market cap | 67.89M | 120.7M | 137.72M | 124.32M | 147.42M | |
Enterprise value | -74.18M | -8.63M | 20.9M | 20.69M | 61.85M | |
P/E ratio | 4.15 | -1.1 | -1.18 | -1.73 | -1.54 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -5.28 | -9.05 | -9.95 | -7.48 | -7.45 | |
PFCF ratio | -5.28 | -9.05 | -9.95 | -7.48 | -7.45 | |
P/B Ratio | 0.45 | 0.93 | 1.3 | 1.3 | 1.89 | |
PTB ratio | 0.45 | 0.93 | 1.3 | 1.3 | 1.89 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 3.52 | 0.41 | -0.77 | -0.96 | -2.89 | |
EV to operating cash flow | 5.77 | 0.65 | -1.51 | -1.24 | -3.12 | |
EV to free cash flow | 5.77 | 0.65 | -1.51 | -1.24 | -3.12 | |
Earnings yield | 0.06 | -0.23 | -0.21 | -0.14 | -0.16 | |
Free cash flow yield | -0.19 | -0.11 | -0.1 | -0.13 | -0.13 | |
Debt to equity | 0 | 0 | 0 | 0.15 | 0.18 | |
Debt to assets | 0 | 0 | 0 | 0.1 | 0.11 | |
Net debt to EBITDA | 6.75 | 6.2 | 4.3 | 4.79 | 4 | |
Current ratio | 8.16 | 5.5 | 3.41 | 3.85 | 3.22 | |
Interest coverage | -13.21 | -18.33 | 0 | 0 | 0 | |
Income quality | 2.62 | 0.54 | 0.48 | 0.93 | 0.83 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.14 | 0.15 | 0.16 | 0.15 | 0.16 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 3.82 | 7.46 | 6.83 | 4.95 | 5.09 | |
ROIC | 0.08 | -0.2 | -0.27 | -0.19 | -0.24 | |
Return on tangible assets | 0.03 | -0.21 | -0.24 | -0.15 | -0.23 | |
Graham Net | 3.99 | 2.74 | 2.09 | 1.82 | 1.32 | |
Working capital | 128.16M | 108.32M | 84.67M | 88.93M | 71.63M | |
Tangible asset value | 127.31M | 107.53M | 83.95M | 74.74M | 57.69M | |
Net current asset value | 126.98M | 107.23M | 83.68M | 74.52M | 57.47M | |
Invested capital | 0 | 0 | 0 | 0.15 | 0.18 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.47M | 2.22M | 5.45M | 8.13M | 5.91M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 236.6 | 259.38 | 948.32 | 864.68 | 471.19 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.38 | 0.35 | 0.09 | 0.1 | 0.19 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.03 | -0.21 | -0.27 | -0.19 | -0.31 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
MNMD Frequently Asked Questions
What is Mind Medicine (MindMed) Inc. stock symbol ?
Mind Medicine (MindMed) Inc. is a CA stock , located in Vancouver of Bc and trading under the symbol MNMD
Is Mind Medicine (MindMed) Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $5. The lowest prediction is $5 and the highest is $5
What is MNMD stock prediction ?
What is Mind Medicine (MindMed) Inc. stock quote today ?
Mind Medicine (MindMed) Inc. stock price is $9.4 today.
Is Mind Medicine (MindMed) Inc. stock public?
Yes, Mind Medicine (MindMed) Inc. is a publicly traded company.